ERBB2 and breast carcinoma: In the EGF100151 trial, lapatinib plus capecitabine reduced the hazard for time-to-disease progression (hazard ratio 0.49; 95% CI 0.34–0.71; P < 0.001) in cases of HER2-positive breast cancer that progressed on anthracycline, a taxane and trastuzuma b[11, 20].